jpm_asset_mgmt
  • Products

    Funds

    • Performance & Yields
    • Liquidity
    • Ultra-Short
    • Short Duration

    Solutions

    • Cash Segmentation
    • Separately Managed Accounts
    • Managed Reserves Strategy
    • Capitalizing on Prime Money Market Funds
  • Insights

    Liquidity Insights

    • Liquidity Insights Overview
    • Audio Commentaries
    • Case Studies
    • Leveraging the Power of Cash Segmentation
    • Cash Investment Policy Statement
    • China Money Market Resource Centre
    • PeerView Survey

    Market Insights

    • Market Insights Overview
    • Eye on the Market
    • Guide to the Markets
    • Market Updates

    Portfolio Insights

    • Portfolio Insights Overview
    • Currency
    • Fixed Income
    • Long-Term Capital Market Assumptions
    • Sustainable Investing
  • Resources
    • MORGAN MONEY
    • Account Management & Trading
    • Multimedia
    • Announcements
    • Total Return Comparison Calculator
  • About us
  • Contact us
Skip to main content
  • English
  • Role
  • Country
  • MORGAN MONEY LOGIN
Search
Menu
CLOSE
Search
You are about to leave the site Close
J.P. Morgan Asset Management’s website and/or mobile terms, privacy and security policies don't apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan Asset Management isn’t responsible for (and doesn't provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan Asset Management name.
CONTINUE Go Back
  1. Home
  2. Insights
  3. Market Insights Overview
  4. Eye on the Market
  5. Coronavirus research

  • Share
  • LinkedIn Twitter Facebook
  • Email
  • Print
  • Actions
  • LinkedIn Twitter Facebook
    Email Print

Coronavirus (COVID-19) research

January 2021

Michael Cembalest

This compilation includes all of our research to-date on the coronavirus. High frequency charts on infection, mortality, economic and market data are updated as data becomes available, usually on a daily basis.

What’s new: US economy showing some signs of slowing after COVID surge (Section 1); Tracking the COVID surge in the US and Europe (Section 2); Vaccination update by country and US state (Section 3); Tracking ICU spare capacity by state (Section 2 and Section 5).

To hear more of Michael Cembalest’s thoughts on global markets and the economy, explore previous versions of Eye on the Market:

READ MORE BY MICHAEL CEMBALEST

Access Michael Cembalest’s COVID Charts of the Week:

VIEW NOW

Our research to-date on the coronavirus:


1. US spending, mobility, and production tracker ›
2. COVID global infection, hospitalization and mortality tracker ›
3. COVID vaccination update and drug development ›
4. COVID: testing for the virus, testing for antibodies and T-cell immunity and survivor impacts ›
5. Detailed virus reports by state ›

1. US spending, mobility, and production tracker

  • High frequency recovery tracking (mobility, manufacturing, retail, air travel, geolocation, oil, hotels, housing, etc.)
  • Real time credit and debit spending data

READ MORE


2. COVID global infection, hospitalization and mortality tracker

  • Global COVID infection snapshot by US state and country (trends, declines from peak levels)
  • US hotspot tracking: infections, hospitalizations, mortality, testing and doctor visits
  • Infection and mortality time series by country
  • How lethal is COVID, and for whom?

READ MORE


3. COVID vaccination update and drug development

  • Preliminary read on Pfizer vaccine efficacy from Israel
  • Vaccination update by country and US state
  • Vaccine coverage timelines by country for vulnerable and total populations
  • How mRNA vaccines, vector vaccines and traditional vaccine types work
  • Pfizer, Moderna and Oxford/Astrazeneca Phase III results
  • Vaccine production, distribution and acceptance challenges
  • The latest news on anti-virals, monoclonal antibodies, convalescent plasma and corticosteroids

READ MORE


4. COVID: testing for the virus and for antibodies, T-cell immune memory and survivor impacts 

  • How virus testing and antibody testing work 
  • Pre-existing T-cell immune memory and COVID
  • The latest seroprevalence tests in US states
  • The issue of falling antibody levels in convalescing patients
  • COVID health impacts on survivors

READ MORE


5. Detailed virus reports by state 

  • One-page reports on each state with charts on infections, hospitalizations, mortality, testing levels, positive test rates, hospital ICU capacity rates and doctor visit indicators

READ MORE

Our research to-date on the coronavirus:


1. The US reopens: tracking US citizens and consumers ›
2. COVID global infection, hospitalization and mortality tracker ›
3. COVID drug development (vaccines, antivirals, mAbs, steroids and blood thinners) ›
4. COVID drug development ›
5. COVID: testing for the virus, testing for antibodies and T-cell immunity and survivor impacts ›
6. Detailed virus reports by state ›

1. The US reopens: tracking US citizens and consumers

  • High frequency recovery tracking (mobility, manufacturing, retail, air travel, geolocation, oil, hotels, housing, etc.)
  • Real time credit and debit spending data

READ MORE


2. COVID global infection, hospitalization and mortality tracker

  • Global COVID infection snapshot (trends, declines from peak levels, threshold levels)
  • US hotspot tracking: infections, hospitalizations, mortality, testing and doctor visits
  • Infection and mortality time series by country

READ MORE


3. COVID drug development (vaccines, antivirals, mAbs, steroids and blood thinners)

  • What we know on the Pfizer/BioNTech vaccine news
  • The latest news on anti-virals, vaccines, monoclonal antibodies, convalescent plasma and corticosteroids
  • Potential benefits of anticoagulants, statins and ACE inhibitors for infected patients

READ MORE


4. COVID drug development 

  • The latest news on anti-virals, vaccines, monoclonal antibodies, convalescent plasma and corticosteroids
  • Potential benefits of anticoagulants, statins and ACE inhibitors for infected patients

READ MORE


5. COVID: testing for the virus and for antibodies, T-cell immune memory and survivor impacts 

  • How virus testing and antibody testing work
  • Latest regional serology results and implications for higher levels of immunity
  • Pre-existing T-cell immune memory and COVID
  • The issue of falling antibody levels in convalescing patients
  • COVID health impacts on survivors

READ MORE


6. Detailed virus reports by state 

  • One-page reports on each state with charts on infections, hospitalizations, mortality, testing levels, positive test rates, hospital bed/ICU utilization rates and doctor visit indicators

READ MORE

This compilation incorporates research and feedback from the Johns Hopkins University Center for Health Security, Harvard Medical School, the University of Toronto Dalla Lana School of Public Health, Washington University Biomedical Sciences Department, the La Jolla Institute for Immunology, the Imperial College of London Department of Infectious Disease Epidemiology and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.


0903c02a8283f910

Listen and Subscribe

 

Listen on Apple Podcasts ›

Subscribe to RSS Feed ›

   

 

Get the latest commentaries in your inbox ›

Follow Michael Cembalest on LinkedIn ›

Markets Volatility Eye on the Market
J.P. Morgan Asset Management

  • Investment stewardship
  • About us
  • Contact us
  • Privacy policy
  • Cookie policy
  • Binding corporate rules
  • Sitemap
  • Accessibility
Decorative
J.P. Morgan

  • J.P. Morgan
  • JPMorgan Chase
  • Chase

READ IMPORTANT LEGAL INFORMATION. CLICK HERE >

The value of investments may go down as well as up and investors may not get back the full amount invested.

Copyright 2021 JPMorgan Chase & Co. All rights reserved.